Vir Biotechnology, Inc.(VIR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VIR Vir Biotechnology, Inc.

Pre-Mkt 06-03 05:09:02 EDT

8.74

-0.29

-3.21%

盘前8.82

+0.08+0.92%

04:28 EDT

High9.02	Low8.73	Vol1.42M
Open8.94	D1 Closing9.03	Amplitude3.21%
Mkt Cap1.47B	Tradable Cap1.11B	Total Shares168.65M
T/O12.47M	T/O Rate1.11%	Tradable Shares127.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VIR","market":"US","secType":"STK","nameCN":"Vir Biotechnology, Inc.","latestPrice":8.74,"timestamp":1780430400000,"preClose":9.03,"halted":0,"volume":1415189,"hourTrading":{"tag":"盘前","latestPrice":8.82,"preClose":8.74,"latestTime":"04:28 EDT","volume":1,"amount":8.82,"timestamp":1780475288052,"change":0.08,"changeRate":0.009153,"amplitude":0},"delay":0,"changeRate":-0.03211517165005528,"floatShares":127000000,"shares":168651974,"eps":-3.140006,"marketStatus":"Pre-Mkt","change":-0.29,"latestTime":"06-03 05:09:02 EDT","open":8.94,"high":9.02,"low":8.73,"amount":12469240.8929175,"amplitude":0.032115,"askPrice":10.47,"askSize":100,"bidPrice":7.94,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.140006,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1780493400000},"marketStatusCode":1,"adr":0,"listingDate":1570766400000,"exchange":"NASDAQ","adjPreClose":8.74,"preHourTrading":{"tag":"盘前","latestPrice":8.82,"preClose":8.74,"latestTime":"04:28 EDT","volume":1,"amount":8.82,"timestamp":1780475288052,"change":0.08,"changeRate":0.009153,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":8.7,"preClose":8.74,"latestTime":"19:58 EDT","volume":30793,"amount":269078.5579,"timestamp":1780444727381,"change":-0.04,"changeRate":-0.004577,"amplitude":0.010297},"volumeRatio":0.728679722173102,"impliedVol":0.1353,"impliedVolPercentile":0.028},"requestUrl":"/m/hq/s/VIR","defaultTab":"news","newsList":[{"id":"2640492606","title":"Vir Biotechnology SVP, Chief Accounting Officer Brent Sabatini sells 379 shares for $3,581.55","url":"https://stock-news.laohu8.com/highlight/detail?id=2640492606","media":"Reuters","labels":["shareholding","insiderTrades"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/2640492606?lang=en_us&edition=fundamental","pubTime":"2026-06-03 05:32","pubTimestamp":1780435941,"startTime":"0","endTime":"0","summary":"Vir Biotechnology SVP and Chief Accounting Officer Brent Sabatini sold 379 common shares on June 1, 2026.Shares sold at $9.45; holdings fell to 61,902 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL9mlHWc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vir Biotechnology SVP, Chief Accounting Officer Brent Sabatini sells 379 shares for $3,581.55","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","VIR","BK4139","BK4568","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640392607","title":"Vir director Janet Napolitano disposes of 3,200 Vir Biotechnology shares for $30,240","url":"https://stock-news.laohu8.com/highlight/detail?id=2640392607","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640392607?lang=en_us&edition=fundamental","pubTime":"2026-06-03 05:35","pubTimestamp":1780436150,"startTime":"0","endTime":"0","summary":"Vir Biotechnology director Janet Napolitano sold 3,200 common shares on June 1, 2026 at USD 9.45.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL21zPY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","VIR","BK4535","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638469428","title":"H.C. Wainwright Sticks to Their Buy Rating for Vir Biotechnology (VIR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638469428","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638469428?lang=en_us&edition=fundamental","pubTime":"2026-05-28 22:47","pubTimestamp":1779979664,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Vir Biotechnology today and set a price target of $20.00. Trucchio covers the H...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-vir-biotechnology-vir-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-vir-biotechnology-vir-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638569687","title":"Vir Biotechnology shareholders elect three directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2638569687","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638569687?lang=en_us&edition=fundamental","pubTime":"2026-05-28 21:06","pubTimestamp":1779973599,"startTime":"0","endTime":"0","summary":"Vir Biotechnology held its annual shareholder meeting on May 26, 2026.Shareholders selected three Class I directors to serve through the 2029 annual meeting.Shareholders backed a non-binding advisory resolution on executive pay.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 28, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL3RFdkt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VIR","BK4585","BK4535","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638068639","title":"Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), GeoVax Labs (GOVX) and Vir Biotechnology (VIR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638068639","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638068639?lang=en_us&edition=fundamental","pubTime":"2026-05-27 21:50","pubTimestamp":1779889808,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AnaptysBio (ANAB), GeoVax Labs (GOVX) and Vir Biotec...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-anaptysbio-anab-geovax-labs-govx-and-vir-biotechnology-vir-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-anaptysbio-anab-geovax-labs-govx-and-vir-biotechnology-vir-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4583","HCSG","BK4137","BK4581","FFTY","BK4535","XBI","BK4588","BK4585","LU0029874061.USD","LU0128526141.USD","GOVX","VIR","XLV","ANAB","LABU","BK4568","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638585215","title":"Assessing Vir Biotechnology (VIR) Valuation After Hepatitis Delta Data Update And Astellas Oncology Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2638585215","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638585215?lang=en_us&edition=fundamental","pubTime":"2026-05-25 08:20","pubTimestamp":1779668429,"startTime":"0","endTime":"0","summary":"Vir Biotechnology (VIR) is back in focus after announcing it will present Phase 2 SOLSTICE trial data for its tobevibart and elebsiran combination in chronic hepatitis delta at the upcoming EASL Congress 2026.\nSee our latest analysis for Vir Biotechnology.\nThe latest SOLSTICE update comes after a period of strong trading interest, with the share price at $9.19, a 90 day share price return of 23.69% and a 1 year total shareholder return of 104.22%. However, multi year total shareholder returns...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/assessing-vir-biotechnology-vir-valuation-after-hepatitis-de","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/assessing-vir-biotechnology-vir-valuation-after-hepatitis-de","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","BK4535","BK4139","VIR","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637971933","title":"Brii Biosciences says arbitration with Vir clouds elebsiran hepatitis B program future","url":"https://stock-news.laohu8.com/highlight/detail?id=2637971933","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637971933?lang=en_us&edition=fundamental","pubTime":"2026-05-22 17:18","pubTimestamp":1779441492,"startTime":"0","endTime":"0","summary":"Brii Biosciences filed a demand for arbitration on April 16, 2026 against Vir Biotechnology at Judicial Arbitration and Mediation Services over alleged breaches of a 2018 collaboration agreement covering the elebsiran hepatitis B program.The dispute also covers a Dec. 19, 2024 letter agreement that shifted drug product formulation manufacturing responsibility from Vir to Brii.The case remains at an early stage with no mutual resolution, leaving the future of elebsiran uncertain.The company cannot commit to a Phase 3 trial of an elebsiran-containing combination therapy until the arbitration claims are resolved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brii Biosciences Ltd. published the original content used to generate this news ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL163838:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK1574","VIR","BK1161","BK4535","02137","BK1587","BK4139","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636863485","title":"Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), MoonLake Immunotherapeutics (MLTX) and Dogwood Therapeutics (DWTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636863485","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636863485?lang=en_us&edition=fundamental","pubTime":"2026-05-20 00:50","pubTimestamp":1779209411,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vir Biotechnology (VIR), MoonLake Immunotherapeutics...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vir-biotechnology-vir-moonlake-immunotherapeutics-mltx-and-dogwood-therapeutics-dwtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vir-biotechnology-vir-moonlake-immunotherapeutics-mltx-and-dogwood-therapeutics-dwtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","LU0128526141.USD","XLV","BK4585","MLTX","BK4568","BK4535","BK4139","HCSG","BK4581","XBI","DWTX","LABU","LU0029874061.USD","BK4588","VIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636700673","title":"BRIEF-Vir Biotechnology To Present Complete Week 96 Data From Mid Stage Solstice Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2636700673","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636700673?lang=en_us&edition=fundamental","pubTime":"2026-05-19 04:07","pubTimestamp":1779134854,"startTime":"0","endTime":"0","summary":"BRIEF-Vir Biotechnology To Present Complete Week 96 Data From Mid Stage Solstice Clinical Trial May 18 (Reuters) - Vir Biotechnology Inc VIR.O:VIR BIOTECHNOLOGY TO PRESENT COMPLETE WEEK 96 DATA FROM P","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA3H5WH2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIR","BK4535","BK4585","BK4139","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636273006","title":"Vir to present Phase 2 SOLSTICE Week 96 hepatitis delta data at EASL 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2636273006","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636273006?lang=en_us&edition=fundamental","pubTime":"2026-05-19 04:06","pubTimestamp":1779134778,"startTime":"0","endTime":"0","summary":"Vir Biotechnology flagged upcoming presentations at EASL Congress 2026 in Barcelona, with complete Week 96 results from its Phase 2 SOLSTICE trial in chronic hepatitis delta scheduled for May 29.The data set will cover efficacy and safety for tobevibart used alone or in combination with elebsiran, aimed at supporting the program’s longer-term benefit-risk profile.A separate Week 48 subgroup analysis is set for poster sessions on May 27 and May 29, examining how body weight factors relate to liver enzyme normalization once viral control is achieved on the combination regimen.The Week 96 readout was selected for “Best of EASL 2026,” signaling elevated visibility for investors tracking late-stage positioning in hepatitis delta.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL8r8p9h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIR","BK4139","BK4585","BK4535","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636006258","title":"Vir Biotechnology to Present Complete Week 96 Data From Phase 2 Solstice Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (Easl) Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2636006258","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636006258?lang=en_us&edition=fundamental","pubTime":"2026-05-19 04:05","pubTimestamp":1779134700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA3H5WH2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","BK4535","BK4585","VIR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633486401","title":"Vir Biotechnology (VIR) Gets a Buy from Bank of America Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2633486401","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633486401?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:37","pubTimestamp":1778150243,"startTime":"0","endTime":"0","summary":"Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Vir Biotechnology today and set a price target of $16.00. Stranahan co...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/vir-biotechnology-vir-gets-a-buy-from-bank-of-america-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/vir-biotechnology-vir-gets-a-buy-from-bank-of-america-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0306807586.USD","LU1668664300.SGD","LU0130517989.USD","BK4504","LU0640476718.USD","LU0130102774.USD","LU1162221912.USD","LU1791807156.HKD","LU0203347892.USD","LU0098860793.USD","IE00BZ1G4Q59.USD","BK4585","LU0256863811.USD","BK4535","VIR","LU0130518102.USD","LU0149725797.USD","LU0203345920.USD","LU0052756011.USD","LU0306806265.USD","IE00BLSP4452.SGD","LU0417517546.SGD","LU0256863902.USD","BK4568","LU0310800965.SGD","LU0868494617.USD","IE00B19Z3581.USD","LU0477156953.USD","LU1894683264.USD","BK4207","IE00B7SZLL34.SGD","PGF","LU1894683348.USD","LU2133065610.SGD","LU1069347547.HKD","LU2129689514.USD","LU0234570918.USD","LU1880398471.USD","LU1267930227.SGD","LU0321505439.SGD","BK4534","LU0070302665.USD","LU0234572021.USD","LU0787776722.HKD","BK4581","LU1363072403.SGD","LU1366192091.USD","BAC","BK4553","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633154492","title":"Vir Biotechnology Q1 EPS USD -0.85","url":"https://stock-news.laohu8.com/highlight/detail?id=2633154492","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633154492?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:19","pubTimestamp":1778098768,"startTime":"0","endTime":"0","summary":"May 06 (Reuters) - Vir Biotechnology Q1 net income USD -125.7 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-MAY-202620:05:46.207 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nRSD7zNcnk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4568","BK4585","VIR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633212151","title":"Vir Biotechnology Q1 net loss widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2633212151","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633212151?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:12","pubTimestamp":1778098371,"startTime":"0","endTime":"0","summary":"Vir Biotechnology Q1 net loss widensOverviewUS biopharma firm's Q1 net loss widened yr/yr as revenue turned negativeCompany ended Q1 with $809.3 mln in cash and investments, excluding Astellas payment","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nL1N41J1CA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","LU0889565916.HKD","ALNY","BK4535","BK4588","LU0114720955.EUR","LU0320765992.SGD","BK4139","BK4548","LU0109394709.USD","BK4585","VIR","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633415904","title":"Vir Biotechnology Q1 2026 GAAP EPS $(0.85) Up From $(0.88) YoY, Sales $(29.000K) Down From $3.032M YoY.","url":"https://stock-news.laohu8.com/highlight/detail?id=2633415904","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633415904?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:07","pubTimestamp":1778098037,"startTime":"0","endTime":"0","summary":"Vir Biotechnology (NASDAQ:VIR) reported quarterly losses of $(0.85) per share. This is a 3.41 percent increase over losses of $(0.88) per share from the same period last year.  The company reported $(29.000 thousand) in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52342931/vir-biotechnology-q1-2026-gaap-eps-0-85-up-from-0-88-yoy-sales-29-000k-down-from-3-032m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vir Biotechnology Q1 2026 GAAP EPS $(0.85) Up From $(0.88) YoY, Sales $(29.000K) Down From $3.032M YoY.","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VIR","BK4568","BK4535","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633511131","title":"Vir Biotechnology Inc - Topline Data From Phase 3 Eclipse 1 Trial Expected in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633511131","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633511131?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:05","pubTimestamp":1778097901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nPLX4DDEC7:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4585","BK4535","BK4568","VIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633291259","title":"Vir Biotechnology CEO joins Bank of America Securities Healthcare Conference fireside chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2633291259","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633291259?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:17","pubTimestamp":1778012257,"startTime":"0","endTime":"0","summary":"Vir Biotechnology CEO Marianne De Backer will join a fireside chat at Bank of America Securities 2026 Healthcare Conference on May 12 at 4:20 p.m. PT in Las Vegas.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire  on May 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL1LwmRg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4535","BK4139","BK4568","VIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633799246","title":"How Insider Sale and VIR-5500 Milestone at Vir Biotechnology (VIR) Have Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2633799246","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633799246?lang=en_us&edition=fundamental","pubTime":"2026-05-05 14:19","pubTimestamp":1777961956,"startTime":"0","endTime":"0","summary":"On 1 May 2026, Vir Biotechnology director Vicki L. Sato sold 22,000 shares under a Rule 10b5-1 plan, while the company and Astellas Pharma completed their collaboration agreement and dosed the first patient in a Phase 1 expansion cohort for VIR-5500 in metastatic prostate cancer.\nThis combination of insider selling and tangible progress in Vir’s oncology pipeline highlights the growing importance of VIR-5500 within its broader development portfolio.\nWe’ll now examine how progress on VIR-5500...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/how-insider-sale-and-vir-5500-milestone-at-vir-biotechnology","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/how-insider-sale-and-vir-5500-milestone-at-vir-biotechnology","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["VIR","BK4585","BK4535","BK4568","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633952285","title":"Vir director Vicki L. Sato disposes of 22,000 shares worth $221,025.20","url":"https://stock-news.laohu8.com/highlight/detail?id=2633952285","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633952285?lang=en_us&edition=fundamental","pubTime":"2026-05-05 00:36","pubTimestamp":1777912579,"startTime":"0","endTime":"0","summary":"Vir Biotechnology director Vicki L. Sato sold 22,000 common shares on May 1, 2026.Sale priced at USD 10.05 per share on weighted-average basis.Directly held stake stood at 1,078,391 shares following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 04, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDLb41hHZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vir director Vicki L. Sato disposes of 22,000 shares worth $221,025.20","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIR","BK4585","BK4139","BK4568","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141691535","title":"Earning Preview: Vir Biotechnology, Inc. Q1 revenue is expected to increase by 1,171.96%, and institutional views are bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1141691535","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141691535?lang=en_us&edition=fundamental","pubTime":"2026-04-30 03:47","pubTimestamp":1777492033,"startTime":"0","endTime":"0","summary":"Abstract Vir Biotechnology, Inc. is scheduled to release its quarterly results on May 6, 2026 Post Market; this preview summarizes consensus expectations, last quarter’s performance, the revenue mix...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Earning Preview: Vir Biotechnology, Inc. Q1 revenue is expected to increase by 1,171.96%, and institutional views are bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vir.bio","stockEarnings":[{"period":"1week","weight":-0.0682},{"period":"1month","weight":-0.126},{"period":"3month","weight":-0.0858},{"period":"6month","weight":0.2891},{"period":"1year","weight":0.7239},{"period":"ytd","weight":0.4494}],"compareEarnings":[{"period":"1week","weight":0.012},{"period":"1month","weight":0.054},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.1098},{"period":"1year","weight":0.2815},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.442895},{"month":2,"riseRate":0.428571,"avgChangeRate":0.063735},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.106207},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.055273},{"month":5,"riseRate":0.571429,"avgChangeRate":0.040281},{"month":6,"riseRate":0.428571,"avgChangeRate":0.005194},{"month":7,"riseRate":0.666667,"avgChangeRate":-0.044477},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.0277},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.115495},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.03118},{"month":11,"riseRate":0.857143,"avgChangeRate":0.105555},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.058058}],"exchange":"NASDAQ","name":"Vir Biotechnology, Inc.","nameEN":"Vir Biotechnology, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vir Biotechnology, Inc.(VIR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vir Biotechnology, Inc.(VIR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vir Biotechnology, Inc.,VIR,Vir Biotechnology, Inc.股票,Vir Biotechnology, Inc.股票老虎,Vir Biotechnology, Inc.股票老虎国际,Vir Biotechnology, Inc.行情,Vir Biotechnology, Inc.股票行情,Vir Biotechnology, Inc.股价,Vir Biotechnology, Inc.股市,Vir Biotechnology, Inc.股票价格,Vir Biotechnology, Inc.股票交易,Vir Biotechnology, Inc.股票购买,Vir Biotechnology, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vir Biotechnology, Inc.(VIR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vir Biotechnology, Inc.(VIR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}